Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 1,095

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

CD19 CAR T-Cell Therapy in Autoimmune Disease — A Case Series with Follow-up

Müller, Fabian, Taubmann, Jule, Bucci, Laura, Wilhelm, Artur, Bergmann, Christina, Völkl, Simon, Aigner, Michael, Rothe, Tobias, Minopoulou, Ioanna, Tur, Carlo, Knitza, Johannes, Kharboutli, Soraya, Kretschmann, Sascha, Vasova, Ingrid, Spoerl, Silvia, Reimann, Hannah, Munoz, Luis, Gerlach, Roman G., Schäfer, Simon, Grieshaber-Bouyer, Ricardo, Korganow, Anne-Sophie, Farge-Bancel, Dominique, Mougiakakos, Dimitrios, Bozec, Aline, Winkler, Thomas, Krönke, Gerhard, Mackensen, Andreas, Schett, Georg·2024·New England Journal of Medicine

Abstract

BACKGROUND: Treatment for autoimmune diseases such as systemic lupus erythematosus (SLE), idiopathic inflammatory myositis, and systemic sclerosis often involves long-term immune suppression. Resetting aberrant autoimmunity in these diseases through deep depletion of B cells is a potential strategy for achieving sustained drug-free remission. METHODS: We evaluated 15 patients with severe SLE (8 patients), idiopathic inflammatory myositis (3 patients), or systemic sclerosis (4 patients) who received a single infusion of CD19 chimeric antigen receptor (CAR) T cells after preconditioning with fludarabine and cyclophosphamide. Efficacy up to 2 years after CAR T-cell infusion was assessed by means of Definition of Remission in SLE (DORIS) remission criteria, American College of Rheumatology-European League against Rheumatism (ACR-EULAR) major clinical response, and the score on the European Scleroderma Trials and Research Group (EUSTAR) activity index (with higher scores indicating greater disease activity), among others. Safety variables, including cytokine release syndrome and infections, were recorded. RESULTS: The median follow-up was 15 months (range, 4 to 29). The mean (±SD) duration of B-cell aplasia was 112±47 days. All the patients with SLE had DORIS remission, all the patients with idiopathic inflammatory myositis had an ACR-EULAR major clinical response, and all the patients with systemic sclerosis had a decrease in the score on the EUSTAR activity index. Immunosuppressive therapy was completely stopped in all the patients. Grade 1 cytokine release syndrome occurred in 10 patients. One patient each had grade 2 cytokine release syndrome, grade 1 immune effector cell-associated neurotoxicity syndrome, and pneumonia that resulted in hospitalization. CONCLUSIONS: In this case series, CD19 CAR T-cell transfer appeared to be feasible, safe, and efficacious in three different autoimmune diseases, providing rationale for further controlled clinical trials. (Funded by Deutsche Forschungsgemeinschaft and others.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa2308917

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 26 references

Cited by

See all 1,095

Metadata

Authors
Müller, F., Taubmann, J., Bucci, L., Wilhelm, A., Bergmann, C., Völkl, S., Aigner, M., Rothe, T., Minopoulou, I., Tur, C., Knitza, J., Kharboutli, S., Kretschmann, S., Vasova, I., Spoerl, S., Reimann, H., Munoz, L., Gerlach, R. G., Schäfer, S., Grieshaber-Bouyer, R., Korganow, A.-S., Farge-Bancel, D., Mougiakakos, D., Bozec, A., Winkler, T., Krönke, G., Mackensen, A., & Schett, G.
Venue
New England Journal of Medicine
Published
2024-02-22
Volume
390
Issue
8
Pages
687-700
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4391990146
Cited by
1,095
References
26
FWCI
168.05
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CD19 CAR T-Cell Therapy in Autoimmune Disease — A Case Series with Follow-up. https://app.cochat.ai/papers/10.1056/nejmoa2308917
The paper
Müller, F., Taubmann, J., Bucci, L., Wilhelm, A., Bergmann, C., Völkl, S., Aigner, M., Rothe, T., Minopoulou, I., Tur, C., Knitza, J., Kharboutli, S., Kretschmann, S., Vasova, I., Spoerl, S., Reimann, H., Munoz, L., Gerlach, R. G., Schäfer, S., . . . Schett, G. (2024). CD19 CAR T-Cell Therapy in Autoimmune Disease — A Case Series with Follow-up. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2308917

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.